What Makes This the Go To Forum for Biopharma Legal Leaders?
The 7th In-House Impact: Biopharma Summit brings together senior legal leaders from across the biopharma ecosystem for two focused days of strategic learning and peer exchange. Expect practical insight on navigating FDA uncertainty, pricing reform, AI adoption, IP protection, compliance maturity and cross-border risk, delivered by GCs and CLOs from some of the industry’s most innovative companies. Designed exclusively for in-house counsel, this summit offers a rare opportunity to benchmark with true peers, strengthen decision-making and return with actionable strategies for 2026’s most pressing legal challenges.
What to Expect?
Interpreting FDA and Policy Signals with Confidence
Hear how senior legal leaders from companies including Samsung Bioepis, Fulcrum Therapeutics and Disc Medicine are reading shifting FDA expectations, anticipating policy swings and strengthening boardlevel decision making in a volatile regulatory year.
Designing Responsible, Scalable AI Governance
Learn how GCs from Enveda Biosciences, Beckman Coulter and Olema Oncology are building enterprisewide AI guardrails, validating model outputs and setting expectations for safe, efficient legal adoption across clinical, regulatory and commercial workflows.
Strengthening Compliance Maturity Across the Development Journey
Discover practical ways Takeda Oncology, Sionna Therapeutics and BeOne Medicines are shaping stageappropriate compliance foundations, clarifying roles and reducing enforcement exposure as teams advance toward commercial readiness.
Safeguarding IP and Trade Secrets in an AIEnabled R&D Environment
Explore how leaders from Umoja Biopharma, Crescent Biopharma and Generate:Biomedicines are aligning scientific, regulatory and legal teams to protect IP, strengthen defensibility and prepare for partner and investor scrutiny.
Improving Deal Readiness Across M&A, Partnerships and IPOs
Gain insight into how Parabilis Medicines, Boundless Bio and Corstasis Therapeutics are preparing for capitalmarket and transaction shifts, building disclosure discipline and reducing diligence surprises to preserve valuation and board confidence.
Shaping the Next Chapter of GC Leadership
Join the final GCled sessions featuring leaders from Indivior, Caribou Biosciences and Arbor Biotechnologies as they share practical insight on board influence, succession planning and strengthening legal leadership in times of change.
Explore the Full Event Guide
- Complete two-day agenda covering regulatory volatility, AI governance, compliance strategy, and deal readiness
- 18+ senior legal leaders across biopharma organizations
- 15+ strategic panel discussions and fireside chats addressing the biggest challenges facing biopharma GCs in 2026
- 8+ hours of dedicated networking, including speed networking and roundtable discussions
- 1 event that brings together senior in-house counsel from across early-stage, growth-stage, and commercial biopharma
Attending Companies Include
Explore the Agenda
Discover the strategies biopharma GCs are using to navigate FDA shifts, pricing reform, AI governance and crossborder risk across two focused days of curated sessions.
Partner With Us
Showcase your expertise to the in-house community and position your brand as a trusted partner shaping biopharma legal strategy in 2026.
Join Biopharma Legal Leaders
Connect with senior in-house counsel from leading biotechs and pharmaceutical companies during highvalue networking designed for meaningful GCtoGC exchange.